Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14293751 | 0.89 | NR1H3 (0.34) | RAB9ASMN1; SMN2CYP2C9NPC1CYP1A2 | |
| SCHEMBL1040692 | 0.89 | NR1H3 (0.47) | RAB9ASMN1; SMN2CYP2C9NPC1CYP1A2 | |
| SCHEMBL14133758 | 0.89 | KDM4C (0.39) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL1041124 | 0.86 | TGM2 (0.46) | RAB9ASMN1; SMN2CYP2C9NPC1CYP1A2 | |
| SCHEMBL1037764 | 0.86 | TDP2 (0.43) | RAB9ASMN1; SMN2NPC1CYP1A2KDM4E | |
| SCHEMBL13072259 | 0.83 | RAB9A (0.39) | RAB9ASMN1; SMN2CYP2C9NPC1CYP1A2 | |
| SCHEMBL1036911 | 0.80 | HRH4 (0.34) | KCNH2 | |
| SCHEMBL4020084 | 0.79 | RAB9A (0.44) | RAB9ASMN1; SMN2CYP2C9NPC1CYP1A2 | |
| SCHEMBL1041001 | 0.79 | MAPK9 (0.46) | RAB9ASMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13596187 | 0.77 | NR1H3 (0.49) | RAB9ASMN1; SMN2CYP2C9NPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051714-B1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-04-13 | — | — | EP | disclosed |
| EP-2051714-B1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-04-13 | — | — | EP | disclosed |
| EP-1853596-B1 | NOVEL, LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-01-26 | — | — | EP | disclosed |
| EP-1853596-B1 | NOVEL, LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| EP-1720546-B1 | NOVEL, SUSTAINED-ACTION BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-1720546-B1 | NOVEL, SUSTAINED-ACTION BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-01 | — | — | EP | disclosed |
| US-20090324510-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20080132556-A1 | 3-HYDROXYMETHYL-4HYDROXY-PHENYL- DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | BOUYSSOU THIERRY | 2008-06-05 | — | — | US | disclosed |
| WO-2008017637-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017637-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017638-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017638-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| EP-1706389-A1 | 3-HYDROXYMETHYL-4-HYDROXY-PHENYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY ILLNESSES | Boehringer Ingelheim International GmbH (DE) | 2006-10-04 | — | — | EP | disclosed |
| US-20060189607-A1 | Long-acting betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
| US-20050234112-A1 | 3-Hydroxymethyl-4-hydroxy-phenyl-derivatives for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
| US-20050197374-A1 | New long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005066140-A1 | 3-HYDROXYMETHYL-4-HYDROXY-PHENYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197374-A1 | New long acting beta-2 agonists and their use as medicaments | ADRB2, ADRA2A, ADRA2C | RAB9A 3247/4885SMN1; SMN2 1639/4885CYP2C9 1701/4885 |
| US-20060189607-A1 | Long-acting betamimetics for the treatment of respiratory complaints | ADRA1A, ADRA1D, ADRA2A | RAB9A 2109/4885SMN1; SMN2 477/4885CYP2C9 1176/4885 |
| US-20090324510-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | NDUFA1, NDUFA6, NDUFA3 | RAB9A 2320/4885SMN1; SMN2 1289/4885CYP2C9 460/4885 |
| US-20050234112-A1 | 3-Hydroxymethyl-4-hydroxy-phenyl-derivatives for the treatment of respiratory diseases | PAH, CYP11B1, CYP11B2 | RAB9A 3364/4885SMN1; SMN2 1960/4885CYP2C9 278/4885 |
| US-20080132556-A1 | 3-HYDROXYMETHYL-4HYDROXY-PHENYL- DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | PAH, CYP1A1, CYP11B1 | RAB9A 2619/4885SMN1; SMN2 2240/4885CYP2C9 196/4885 |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | ADRB1, ADRA1A, ADRB2 | RAB9A 1903/4885SMN1; SMN2 1409/4885CYP2C9 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.